CEPTAZ Drug Patent Profile
✉ Email this page to a colleague
When do Ceptaz patents expire, and when can generic versions of Ceptaz launch?
Ceptaz is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in CEPTAZ is ceftazidime. There are seventeen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ceftazidime profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ceptaz
A generic version of CEPTAZ was approved as ceftazidime by ACS DOBFAR on November 20th, 1985.
Summary for CEPTAZ
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 42 |
Patent Applications: | 8,442 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CEPTAZ at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for CEPTAZ
US Patents and Regulatory Information for CEPTAZ
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | CEPTAZ | ceftazidime | INJECTABLE;INJECTION | 050646-002 | Sep 27, 1990 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Glaxosmithkline | CEPTAZ | ceftazidime | INJECTABLE;INJECTION | 050646-001 | Sep 27, 1990 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Glaxosmithkline | CEPTAZ | ceftazidime | INJECTABLE;INJECTION | 050646-003 | Sep 27, 1990 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Glaxosmithkline | CEPTAZ | ceftazidime | INJECTABLE;INJECTION | 050646-004 | Sep 27, 1990 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |